The oral delivery of BCS-III and BCS-IV small molecules has two key challenges: solubility and permeability. ProPerma® uniquely improves both permeability and bioavailability of BCS-III and BCS-IV small molecules by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients. Our “formulation toolbox” of excipients falls within the pharmaceutically accepted domain.
Unlike other technologies, ProPerma® improves both permeability and bioavailability by deploying a smart combination of pH-lowering, membrane wetting, charge dispersal and solubilizing agents without making physicochemical modifications to the partner’s API.
Enteris has demonstrated positive results in several clinical studies, including pivotal Phase 3 trials. As a true full-service partner of choice, Enteris BioPharma is uniquely qualified to provide integrated support from the earliest stages of research through late stage clinical trials.
ProPerma® Mechanism of Delivery in Four Key Steps
Enteris’s ProPerma® oral formulation technology is made up of two key components, the first is a permeation enhancer, which loosens tight junctions in the intestinal enterocytes and allows paracellular transport. The permeation enhancer, a surfactant, also acts as a great solubilizing agent. The other main excipient, citric acid, also plays an active, multifunctional role in transport by acting as a calcium chelator and membrane permeation enhancer, a pH-lowering agent that increases absorptive flux, and a membrane wetting/charge dispersal agent.
Enteris has demonstrated its ability to effectively deliver a variety of molecules across multiple therapeutic indications.